Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Erika G. García"'
Autor:
Ruben Burgos-Vargas, Karina Santana, Haiyun Fan, Virginia Pascual-Ramos, Mario H. Cardiel, Erika G. García, Ehab Mahgoub, Carlos Abud-Mendoza, Ricardo Rojo, Daniel Xibille, Mahboob Rahman, César Pacheco-Tena
Publikováno v:
Reumatología Clínica (English Edition). 15:43-53
Objectives Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We characterized efficacy and safety of tofacitinib in Mexican patients from RA Phase 3 and long-term extension (LTE) studies. Methods Data from
Autor:
William J. Otero Escalante, Katherine Persand, Juan José Jaller, Ricardo Rojo, Giovanna A. Matiz, Patricia Velez, Erika G. García, Douglass Chapman
Publikováno v:
Revista Colombiana de Reumatología, Volume: 25, Issue: 4, Pages: 233-244, Published: DEC 2018
Introduction: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Objective: To conduct a post hoc analysis of tofacitinib efficacy and safety in Colombian patients enrolled in global phase III studies. Metho
Autor:
Gustavo Citera, Erika G. García, Ricardo Rojo, Andrea Barranjard Vannucci Lomonte, Sebastião Cezar Radominski, Mario H. Cardiel, Kenneth Kwok, Juan José Jaller, Patricia Velez, Daniel Xibille, Pedro M. A. Miranda, Annelise Goecke
Publikováno v:
Reumatología Clínica. 13:201-209
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assessed tofacitinib efficacy and safety in the Latin American (LA) subpopulation of global Phase 3 and long-term extension (LTE) studies. Mate
Autor:
Erika G. García, Kenneth Kwok, Carlos Alvarez-Moreno, Oscar Rillo, Gustavo Citera, Felix J. Romero, Sebastião Cezar Radominski, Mario H. Cardiel, Juan José Jaller, Ricardo Rojo, Graciela Castelli, Dario Ponce de Leon, Ariel Salinas, Oswaldo Castañeda, Eduardo Mysler
Publikováno v:
JCR: Journal of Clinical Rheumatology. 23:193-199
Rheumatoid arthritis (RA) is a chronic, autoimmune disease characterized by joint destruction. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post hoc analysis assessed the safety of tofacitinib in Latin American (LA) pat
Autor:
Erika G. García, Ricardo Rojo, Dario Ponce de Leon, Ermeg Akylbekova, Claiton Viegas Brenol, Sebastião Cezar Radominski, Cristiano A. F. Zerbini, Flora M. D'Andrea Marcolino, Andrea Barranjard Vannucci Lomonte
Publikováno v:
Medicine
Supplemental Digital Content is available in the text
Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy and safety of tofacitinib in Brazilian patients from Phase 2 (P2) and Phase
Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy and safety of tofacitinib in Brazilian patients from Phase 2 (P2) and Phase